
  
    
      
        
        As_IN the_DT Hispanic_JJ world_NN well_RB knows_VBZ ,_, the_DT word_NN in_IN Spanish_JJ for_IN advertising_NN is_VBZ ‘ propaganda_NN’ ,_,
        its_PRP$ meaning_VBG derived_VBN literally_RB from_IN the_DT propagation_NN of_IN the_DT faith_NN ,_, the_DT antithesis_NNS of_IN
        science_NN 's_POS Enlightenment_NNP ideals_NNS ._. The_DT old_JJ word_NN somehow_RB seems_VBZ perfect_JJ for_IN describing_VBG the_DT new_JJ
        world_NN of_IN drug_NN promotion_NN and_CC its_PRP$ growing_VBG use_NN of_IN the_DT famous_JJ face_NN ._. Like_IN the_DT catholic_JJ cardinals_NNS
        of_IN the_DT 17_CD th_NN century_NN ,_, many_JJ of_IN the_DT feted_JJ celebrities_NNS of_IN the_DT 21_CD st_NN are_VBP now_RB engaged_VBN in_IN spreading_VBG
        the_DT word_NN ._. Now_RB ,_, as_IN then_RB ,_, the_DT religion_NN promises_VBZ miraculous_JJ breakthroughs_NNS ,_, wonder_VBP cures_NNS ,_, and_CC
        sometimes_RB even_RB eternal_JJ life_NN ._. The_DT difference_NN is_VBZ that_IN this_DT time_NN around_RP ,_, the_DT stars_NNS are_VBP earning_VBG
        fat_JJ fees_NNS from_IN the_DT marketing_NN departments_NNS of_IN giant_NN pharmaceutical_JJ companies_NNS ._. And_CC if_IN the_DT
        latest_JJS revelations_NNS from_IN industry_NN insiders_NNS are_VBP anything_NN to_TO go_VB by_RB ,_, their_PRP$ hefty_JJ investments_NNS in_IN
        celebrity_NN selling_VBG are_VBP well_RB worth_JJ it_PRP ._.
      
      
        Celebrity_NNP Selling_NNP
        The_DT epicentre_NN of_IN this_DT phenomenon_NN is_VBZ of_IN course_NN the_DT United_NNP States_NNPS ,_, where_WRB companies_NNS
        routinely_RB hire_VBP celebrities_NNS to_TO attract_VB attention_NN to_TO the_DT latest_JJS drugs_NNS and_CC the_DT diseases_NNS that_WDT
        go_VBP with_IN them_PRP ._. Pfizer_NNP famously_RB paid_VBD presidential_JJ hopeful_JJ Bob_NNP Dole_NNP to_TO promote_VB awareness_NN of_IN
        erectile_NN dysfunction_NN as_IN sildenafil_NN (_( Viagra_NNP )_) was_VBD hitting_VBG the_DT market_NN ._. Wyeth_NNP hired_VBD supermodel_NN
        Lauren_NNP Hutton_NNP to_TO hawk_NN hormone_NN replacement_NN therapy_NN and_CC menopause_NN ._. GSK_NNP contracted_VBD football_NN
        star_NN Ricky_NNP Williams_NNP to_TO sell_VB social_JJ anxiety_NN disorder_NN ,_, helping_VBG make_NN paroxetine_NN
        (_( Paxil_NNP )_) —_NN briefly—the_NN world_NN 's_POS top-selling_JJ antidepressant_NN ._. Even_RB the_DT dead_JJ are_VBP raising_VBG
        awareness_NN ,_, with_IN the_DT estate_NN of_IN Errol_NNP Flynn_NNP now_RB enlisted_VBD to_TO help_VB promote_VB cardiovascular_JJ
        disease_NN as_IN a_DT household_NN name_NN [_NN 1_CD ]_NN ._. The_DT celebrity_NN ,_, living_VBG or_CC dead_JJ ,_, becomes_VBZ integral_JJ to_TO a_DT drug_NN
        marketing_NN strategy_NN that_WDT includes_VBZ paid_VBN advertising_NN and_CC aggressive_JJ public_JJ relations_NNS campaigns_NNS
        that_WDT can_MD produce_VB media_NNS appearances_NNS on_IN the_DT likes_NNS of_IN 
        Oprah_NNP and_CC 
        The_DT Today_NNP Show_NNP ._. According_VBG to_TO celebrity_NN brokers_NNS ,_, the_DT star_NN 's_POS remuneration_NN
        package_NN ,_, though_IN always_RB confidential_JJ ,_, can_MD range_VB from_IN $_$ 20_CD ,_, 000_CD to_TO $_$ 2_CD million_CD ._.
        ‘ A_DT partnership_NN between_IN a_DT celebrity_NN and_CC a_DT brand_NN has_VBZ an_DT intangible_JJ sort_NN of_IN magic_JJ’ ,_, writes_VBZ
        a_DT senior_JJ marketing_NN executive_NN at_IN Amgen_NNP ,_, in_IN an_DT extremely_RB candid_JJ piece_NN published_VBN recently_RB in_IN
        an_DT industry_NN trade_NN magazine_NN [_NN 2_CD ]_NN ._. Amgen_NNP is_VBZ the_DT Californian_NN biotech_JJ firm_NN that_WDT hired_VBD handsome_JJ
        ‘ West_NNP Wing_NNP’ star_NN Rob_NNP Lowe_NNP to_TO help_VB market_VB an_DT anti-infection_JJ drug_NN ._. Lowe_NNP was_VBD reportedly_RB paid_VBN
        more_JJR than_IN $_$ 1_CD million_CD by_IN Amgen_NNP ,_, though_IN there_EX is_VBZ speculation_NN that_DT part_NN of_IN the_DT fee_NN might_MD flow_VB
        to_TO charity_NN [_NN 3_CD ]_NN ._. In_IN her_PRP$ report_NN ,_, Amgen_NNP 's_POS Osnat_NNP Benshoshan_NNP shares_NNS some_DT thoughtful_JJ tips_NNS with_IN
        her_PRP$ peers_NNS among_IN the_DT pharmaceutical_JJ marketing_NN fraternity_NN :_: ‘ use_NN an_DT A-_NNP list_NN celebrity_NN’ ;_: find_VB a_DT
        ‘ news-hook_JJ’ that_IN links_VBZ the_DT celebrity_NN and_CC your_PRP$ product_NN ;_: develop_VB some_DT simple_JJ messages_NNS ;_: and_CC
        make_VB sure_JJ the_DT celebrity_NN delivers_VBZ them_PRP at_IN every_DT appearance_NN ._.
        Benshoshan_NNP then_RB reveals_VBZ why_WRB on-air_JJ talk-show_NN appearances_NNS on_IN ‘ top-tier_JJ media_NNS venues_NNS’ like_IN
        
        The_DT Rosie_NNP Show_NNP can_MD be_VB better_JJR forums_NNS for_IN celebrities_NNS than_IN straight_JJ
        advertisements_NNS ,_, which_WDT are_VBP governed_VBN by_IN regulations_NNS ._. ‘ The_DT great_JJ advantage_NN over_IN advertising_NN is_VBZ
        that_IN the_DT airtime_NN is_VBZ practically_RB free_JJ ,_, and_CC there_EX is_VBZ no_DT fair_JJ balance_NN to_TO worry_VB about_IN’ she_PRP
        writes_VBZ [_NN 2_CD ]_NN ._. The_DT downside_NN with_IN a_DT media_NNS interview_NN ,_, she_PRP laments_VBZ ,_, is_VBZ that_WDT compared_VBD to_TO a_DT
        scripted_JJ ad_NN ,_, ‘ the_DT situation_NN is_VBZ less_RBR controllable_JJ ._. It_PRP can_MD be_VB tricky_JJ for_IN the_DT celebrity_NN to_TO
        ensure_VB that_IN all_DT product_NN messages_NNS are_VBP delivered_VBN …_NN ._.’ Her_PRP$ other_JJ big_JJ tip_NN for_IN drug-makers_JJ is_VBZ to_TO
        rate_NN your_PRP$ prospective_JJ celebrity_NN with_IN a_DT ‘ Q_NNP score_NN’ ,_, a_DT measure_NN of_IN their_PRP$ likeability_NN and_CC
        recognisability_NN with_IN the_DT public_NN ._. Apparently_RB Rob_NNP Lowe_NNP 's_POS Q_NNP score_NN was_VBD high_JJ with_IN women_NNS over_IN
        fifty_NN ,_, a_DT key_JJ target_NN of_IN the_DT Amgen_NNP campaign_NN [_NN 3_CD ]_NN ._.
        Another_DT recent_JJ report_NN from_IN within_IN the_DT industry_NN draws_VBZ on_IN public_JJ opinion_NN survey_NN data_NNS to_TO
        guide_VB drug_NN company_NN marketers_NNS on_IN the_DT selection_NN and_CC ‘ effective_JJ use_NN’ of_IN celebrity_NN
        spokespersons_NNS [_NN 4_CD ]_NN ._. The_DT survey_NN was_VBD conducted_VBN by_IN a_DT Seattle_NNP firm_NN called_VBD NexCura_NNP Inc_NNP ._. ,_, in_IN
        partnership_NN with_IN the_DT trade_NN magazine_NN that_WDT published_VBD the_DT study_NN ._. The_DT major_JJ findings_NNS echo_VBP the_DT
        insights_NNS of_IN the_DT Amgen_NNP executive_NN about_IN credibility_NN ,_, and_CC underline_VB the_DT importance_NN of_IN your_PRP$
        star_NN being_VBG perceived_VBN as_RB generally_RB trustworthy_NN ,_, and_CC specifically_RB knowledgeable_JJ about_IN the_DT
        condition_NN on_IN which_WDT they_PRP are_VBP hired_VBN to_TO speak_VB ._. Perhaps_RB not_RB surprisingly_RB ,_, the_DT survey_NN found_VBD that_IN
        people_NNS diagnosed_VBN as_IN suffering_VBG chronic_JJ conditions_NNS were_VBD far_RB more_RBR attentive_JJ to_TO celebrity_NN
        messages_NNS on_IN health_NN than_IN the_DT general_JJ public_NN ._.
        The_DT issue_NN of_IN credibility_NN is_VBZ important_JJ ,_, the_DT NexCura_NNP Inc_NNP ._. researchers_NNS point_VBP out_IN ,_, because_IN
        ‘ the_DT credibility_NN rating_NN is_VBZ used_VBN as_IN a_DT surrogate_NN for_IN “ buying_VBG” behavior_NN’ —_NN an_DT intermediate_JJ
        measure_NN of_IN whether_IN the_DT star_NN can_MD persuade_VB people_NNS to_TO request_VB the_DT target_NN drug_NN from_IN their_PRP$
        doctor_NN ._. The_DT survey_NN found_VBD that_IN Bob_NNP Dole_NNP was_VBD still_RB the_DT most_RBS recognisable_JJ celebrity_NN marketer_NN
        with_IN the_DT United_NNP States_NNPS public_JJ ,_, but_CC that_IN the_DT skater_NN Dorothy_NNP Hamill—currently_NNP promoting_VBG
        Merck_NNP 's_POS arthritis_NN medication_NN rofecoxib_NN (_( Vioxx_NNP )_) —_NN took_VBD the_DT lead_NN in_IN the_DT credibility_NN stakes_NNS ._.
        Significantly_RB though_RB ,_, almost_RB three-quarters_NNS of_IN those_DT surveyed_VBN were_VBD correctly_RB able_JJ to_TO
        identify_VB Bob_NNP Dole_NNP with_IN Pfizer_NNP 's_POS Viagra_NNP ,_, despite_IN the_DT fact_NN that_IN the_DT advertisements_NNS in_IN which_WDT
        he_PRP appeared_VBD were_VBD ‘ unbranded_JJ’ ads_NNS for_IN erectile_NN dysfunction_NN ._. The_DT researchers_NNS concluded_VBN by_IN
        recommending_VBG that_IN drug_NN companies_NNS choose_VBP a_DT celebrity_NN with_IN personal_JJ experience_NN of_IN the_DT target_NN
        condition_NN ;_: choose_VB someone_NN trustworthy—perhaps_NNS a_DT newsreader_NN or_CC sports_NNS figure_VBP ;_: and_CC choose_VB
        someone_NN who_WP will_MD promote_VB a_DT single_JJ cause_NN or_CC brand_NN rather_RB than_IN multiple_JJ ones_NNS ._.
        Ironically_RB ,_, the_DT NexCura_NNP survey_NN also_RB found_VBD two-thirds_NNS of_IN medical_JJ consumers_NNS agreed_VBD with_IN
        the_DT proposition_NN that_IN celebrities_NNS were_VBD ‘ just_RB doing_VBG it_PRP for_IN the_DT money_NN and_CC ca_MD n't_RB be_VB
        trusted_VBN’ ._.
      
      
        The_DT Trouble_NN with_IN Celebrity_NNP Selling_NNP
        The_DT first_JJ problem_NN here_RB is_VBZ that_IN the_DT public_NN is_VBZ often_RB not_RB even_RB informed_VBN whether_IN a_DT celebrity_NN
        is_VBZ receiving_VBG money_NN from_IN a_DT drug_NN company_NN ._. In_IN the_DT case_NN of_IN TV_NN star_NN Rob_NNP Lowe_NNP ,_, there_EX was_VBD no_DT
        mandated_VBN requirement_NN for_IN him_PRP to_TO disclose_VB his_PRP$ link_NN with_IN Amgen_NNP when_WRB appearing_VBG on_IN media_NNS shows_VBZ
        watched_VBN by_IN millions_NNS ._. According_VBG to_TO one_CD industry_NN insider_NN familiar_JJ with_IN the_DT case_NN ,_, who_WP did_VBD not_RB
        want_VB to_TO be_VB named_VBN ,_, ‘ it_PRP depended_VBD if_IN he_PRP remembered_VBD to_TO say_VB it_PRP ,_, and_CC whether_IN he_PRP was_VBD asked_VBN’ ._. The_DT
        media_NNS 's_POS failure_NN to_TO disclose_VB relevant_JJ conflicts_NNS of_IN interest_NN when_WRB covering_VBG healthcare_NN is_VBZ well_RB
        established_VBN [_NN 5_CD ]_NN ._. When_WRB 
        Frasier_NNP star_NN Kelsey_NNP Grammer_NNP and_CC his_PRP$ wife_NN were_VBD promoting_VBG irritable_JJ bowel_NN
        syndrome_NN on_IN top-rating_JJ TV_NN shows_NNS ,_, viewers_NNS thought_VBD the_DT pair_NN were_VBD speaking_VBG on_IN behalf_NN of_IN an_DT
        independent_JJ foundation_NN ._. In_IN fact_NN the_DT couple_NN 's_POS fee_NN had_VBD flowed_VBD from_IN GSK_NNP ,_, which_WDT was_VBD at_IN that_DT
        time_NN preparing_VBG the_DT market_NN for_IN alosetron_NN (_( Lotronex_NNP )_) ,_, a_DT controversial_JJ new_JJ drug_NN that_WDT carried_VBD
        modest_JJ benefits_NNS and_CC severe_JJ side_NN effects_NNS ,_, including_VBG possible_JJ death_NN [_NN 6_CD ]_NN ._.
        Equally_RB as_IN serious_JJ is_VBZ the_DT lack_NN of_IN any_DT formal_JJ requirement_NN for_IN stars_NNS or_CC media_NNS outlets_NNS to_TO
        spell_VB out_IN drug_NN side_NN effects_NNS along_IN with_IN benefits_NNS when_WRB celebrities_NNS are_VBP pushing_VBG products_NNS or_CC
        conditions_NNS ._. Lauren_NNP Hutton_NNP can_MD be_VB quoted_VBN ,_, in_IN magazine_NN articles_NNS read_VBN by_IN millions_NNS of_IN readers_NNS ,_,
        as_IN saying_VBG ,_, ‘ My_PRP$ No_UH ._. 1_LS secret_NN is_VBZ estrogen_NN’ without_IN any_DT need_NN for_IN her_PRP$ ,_, or_CC the_DT magazine_NN ,_, to_TO list_VB
        the_DT dangers_NNS of_IN the_DT hormone_NN replacement_NN therapy_NN made_VBN by_IN her_PRP$ sponsor_NN [_NN 7_CD ]_NN ._. But_CC perhaps_RB most_RBS
        troubling_VBG is_VBZ the_DT way_NN celebrities_NNS ,_, with_IN their_PRP$ star_NN power_NN ,_, can_MD help_VB to_TO fundamentally_RB shift_VB
        the_DT public_JJ debate_NN about_IN major_JJ health_NN problems_NNS ._.
        While_IN Prince_NNP Charles_NNP 's_POS companion_NN Camilla_NNP Parker_NNP Bowles_NNP takes_VBZ no_DT money_NN from_IN drug_NN
        companies_NNS ,_, she_PRP did_VBD choose_VB to_TO make_VB an_DT important_JJ public_JJ statement_NN about_IN the_DT bone_NN condition_NN
        osteoporosis_NNS at_IN an_DT international_JJ conference_NN funded_VBN by_IN Lilly_NNP ,_, a_DT company_NN promoting_VBG a_DT
        medication_NN for_IN the_DT condition_NN [_NN 8_CD ]_NN ._. Camilla_NNP 's_POS call_NN for_IN early_JJ intervention_NN and_CC greater_JJR use_NN of_IN
        expensive_JJ tests_NNS and_CC technologies_NNS for_IN the_DT primary_JJ prevention_NN of_IN osteoporosis_NNS drew_VBD on_IN
        materials_NNS sponsored_VBN by_IN the_DT pharmaceutical_JJ industry_NN ,_, and_CC was_VBD synchronised_JJ with_IN simplistic_JJ
        industry_NN marketing_NN messages_NNS ._. Camilla_NNP 's_POS high-profile_JJ intervention_NN at_IN a_DT drug_NN company_NN
        sponsored_VBD forum_NN ,_, albeit_IN unwittingly_RB ,_, helps_VBZ keep_VB the_DT focus_NN on_IN biochemical_JJ causes_NNS of_IN ,_, and_CC
        biochemical_JJ solutions_NNS to_TO ,_, the_DT much_RB wider_RBR public_JJ health_NN problem_NN of_IN fractures_NNS ._. Moreover_RB these_DT
        simple_JJ marketing_NN messages_NNS undermine_VBP the_DT complexity_NN of_IN the_DT cost-effectiveness_JJ arguments_NNS that_WDT
        are_VBP central_JJ to_TO any_DT rational_JJ debate_NN about_IN the_DT equitable_JJ distribution_NN of_IN health_NN care_NN
        resources_NNS ._. Other_JJ high-profile_JJ figures_NNS attending_VBG the_DT same_JJ conference_NN eagerly_RB accepted_VBD Lilly_NNP
        money_NN ,_, and_CC one_CD ,_, former_JJ Texas_NNP Governor_NNP Ann_NNP Richards_NNP ,_, blatantly_RB promoted_VBN Lilly_NNP 's_POS drug_NN during_IN
        an_DT interview_NN on_IN CNN_NNP 's_POS Larry_NNP King_NNP Show_NNP just_RB days_NNS later_RB [_NN 8_CD ]_NN ._.
      
      
        The_DT Future_NNP of_IN Celebrity_NNP Selling_NNP
        With_IN pharmaceutical_JJ marketing_NN ,_, it_PRP is_VBZ clear_JJ that_DT nothing_NN short_JJ of_IN a_DT Vatican_NNP II-style_NNP
        reform_NN is_VBZ required_VBN ,_, though_IN there_EX are_VBP already_RB encouraging_VBG signs_NNS of_IN change_NN ._. Scientific_JJ
        journals_NNS are_VBP slowly_RB disentangling_VBG themselves_PRP from_IN unhealthy_JJ industry_NN influence_NN over_IN what_WP
        they_PRP publish_VB ,_, and_CC public_JJ access_NN to_TO clinical_JJ trial_NN data_NNS is_VBZ daily_JJ a_DT closer_JJR reality_NN [_NN 9_CD ]_NN ._.
        However_RB ,_, a_DT less_RBR distorted_JJ scientific_JJ record_NN about_IN healthcare_NN products_NNS is_VBZ meaningless_JJ
        without_IN regulations_NNS on_IN how_WRB important_JJ science_NN is_VBZ communicated_VBN to_TO the_DT public_NN ._. Celebrities_NNP
        paid_VBN by_IN drug_NN companies_NNS to_TO promote_VB drugs_NNS ,_, or_CC ‘ raise_VB awareness_NN’ about_IN disease_NN ,_, should_MD be_VB
        subject_JJ to_TO the_DT same_JJ rules_NNS as_IN direct-to-consumer_JJ advertising_NN ,_, which_WDT would_MD mean_VB prohibition_NN
        in_IN many_JJ nations_NNS and_CC much_RB more_JJR fulsome_NN disclosure_NN in_IN the_DT United_NNP States_NNPS than_IN is_VBZ currently_RB the_DT
        case_NN ._. At_IN the_DT very_RB least_JJS ,_, public_JJ disclosure_NN of_IN a_DT product_NN 's_POS risks_NNS and_CC benefits_NNS ,_, and_CC the_DT
        magnitude_NN of_IN the_DT celebrity_NN 's_POS fee_NN ,_, should_MD be_VB mandatory_JJ and_CC routine_JJ ._. Let_VB 's_PRP see_VB what_WP that_WDT does_VBZ
        to_TO their_PRP$ Q_NNP rating_NN ._.
      
    
  
